Literature DB >> 21168236

Assessment of lung-cancer mortality reduction from CT Screening.

Claudia I Henschke1, Paolo Boffetta, Olga Gorlova, Rowena Yip, John O Delancey, Millennia Foy.   

Abstract

BACKGROUND: CT screening has been shown to increase lung cancer curability and we now assess the corresponding reduction in lung cancer mortality.
METHODS: Lung-cancer mortality in a cohort of 7995 smokers who underwent CT screening for lung cancer in New York State (NYS) was compared with two unscreened cohorts (CPS-II and CARET). The standardized mortality ratio (SMR) of observed to expected lung cancer deaths for NYS was jointly adjusted for age, sex, and smoking history. As more current NYS smokers might have quit as a result of the screening, thus reducing deaths from lung cancer, another analysis was restricted to those participants smoking at entry and still smoking 6 years later.
RESULTS: The SMR was 64/99.8=0.64 (P = 0.84 × 10⁻⁴) and 28/77.6=0.36 (P = 0.83 × 10⁻¹⁰), showing a significant reduction in deaths from lung cancer of 36% and 64% for CPS-II and CARET, respectively. Considering participants who were smoking at entry and still smoking 6 years later, the SMR using CPS-II rates was 29/49.1 = 0.59 (P = 0.001) and using CARET rates it was 21/57.4 = 0.37 (P = 0.31 × 10⁻⁷).
CONCLUSIONS: CT screening significantly reduces lung-cancer mortality.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21168236     DOI: 10.1016/j.lungcan.2010.10.025

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  20 in total

1.  Aberrant expression of microRNAs in serum may identify individuals with pancreatic cancer.

Authors:  Mao-Song Lin; Wei-Chang Chen; Jun-Xing Huang; Heng-Jun Gao; Hai-Hui Sheng
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  A case of early stage lung cancer detected by repeated cancer screening with positron emission tomography.

Authors:  Ikuko Sakata; Yuichi Ozeki; Katsumi Tamura; Jiro Ishida; Shinsuke Aida; Yoshiyuki Abe
Journal:  Oncol Lett       Date:  2011-11-22       Impact factor: 2.967

Review 3.  Quality assurance and quantitative imaging biomarkers in low-dose CT lung cancer screening.

Authors:  Chara E Rydzak; Samuel G Armato; Ricardo S Avila; James L Mulshine; David F Yankelevitz; David S Gierada
Journal:  Br J Radiol       Date:  2017-10-27       Impact factor: 3.039

Review 4.  Lung cancer screening guidelines: common ground and differences.

Authors:  Swati Gulati; James L Mulshine
Journal:  Transl Lung Cancer Res       Date:  2014-06

Review 5.  Risk factors assessment and risk prediction models in lung cancer screening candidates.

Authors:  Mariusz Adamek; Ewa Wachuła; Sylwia Szabłowska-Siwik; Agnieszka Boratyn-Nowicka; Damian Czyżewski
Journal:  Ann Transl Med       Date:  2016-04

Review 6.  The importance of the regimen of screening in maximizing the benefit and minimizing the harms.

Authors:  Claudia I Henschke; Kunwei Li; Rowena Yip; Mary Salvatore; David F Yankelevitz
Journal:  Ann Transl Med       Date:  2016-04

7.  Chemoprevention by N-acetylcysteine of low-dose CT-induced murine lung tumorigenesis.

Authors:  Mark Steven Miller; Joseph E Moore; Matthew C Walb; Nancy D Kock; Albert Attia; Scott Isom; Jennifer E McBride; Michael T Munley
Journal:  Carcinogenesis       Date:  2012-10-26       Impact factor: 4.944

Review 8.  Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Douglas E Wood; Ella A Kazerooni; Scott L Baum; George A Eapen; David S Ettinger; Lifang Hou; David M Jackman; Donald Klippenstein; Rohit Kumar; Rudy P Lackner; Lorriana E Leard; Inga T Lennes; Ann N C Leung; Samir S Makani; Pierre P Massion; Peter Mazzone; Robert E Merritt; Bryan F Meyers; David E Midthun; Sudhakar Pipavath; Christie Pratt; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Peter B Sachs; Matthew B Schabath; Mark L Schiebler; Betty C Tong; William D Travis; Benjamin Wei; Stephen C Yang; Kristina M Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

9.  Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers.

Authors:  Jun Shen; Ziling Liu; Nevins W Todd; Howard Zhang; Jipei Liao; Lei Yu; Maria A Guarnera; Ruiyun Li; Ling Cai; Min Zhan; Feng Jiang
Journal:  BMC Cancer       Date:  2011-08-24       Impact factor: 4.430

10.  From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF).

Authors:  S Couraud; A B Cortot; L Greillier; V Gounant; B Mennecier; N Girard; B Besse; L Brouchet; O Castelnau; P Frappé; G R Ferretti; L Guittet; A Khalil; P Lefebure; F Laurent; S Liebart; O Molinier; E Quoix; M-P Revel; B Stach; P-J Souquet; P Thomas; J Trédaniel; E Lemarié; G Zalcman; F Barlési; B Milleron
Journal:  Ann Oncol       Date:  2012-11-07       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.